vendredi 23 septembre 2016

Onco Actu du 23 septembre 2016

1. Biologie

Creative Minds: Making a Miniature Colon in the Lab [NIH Director's Blog]

Breast cancer’s spread may be influenced by circadian gene [Reuters]

3.1 Tabac

Ever-Use and Curiosity About Cigarettes, Cigars, Smokeless Tobacco, and Electronic Cigarettes Among US Middle and High School Students, 2012–2014 [CDC]

5. Traitements

New triple therapy could boost treatment and prevent relapse in head and neck cancer [The Institute of Cancer Research]

5.10 Traitements - Essais

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data [The Street]

5.12 Immunothérapies

The next checkpoints? Immuno-oncology upstart looks to find new ways to unleash T cells [EndPoints]

German next-gen checkpoint inhibitor startup reels in €40M [FierceBiotech]

5.2 Pharma

In Turnaround Saga, Ignyta Nears Crucial Phase in Cancer Drug Trial [Xconomy]

Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients [Novartis]

5.3 Traitements - FDA, EMA,...

Sarepta Wins Controversial FDA Approval for First DMD Drug [RAPS]

The FDA Did The Right Thing By Approving a Novel Drug For A Disabling Disease [Forbes]

5.6 ESMO

Precision medicine trial first of its kind to show benefit to patients [ESMO]

6. Lutte contre les cancers

Forging Collaborations to Spur Global Progress against Cancer [NCI]

6.11 Patients

One dying patient taught me that doing nothing can be brave [The Guardian]

6.3 Associations/Fondations

New research effort taking the long view with Facebook founder’s $3 billion [STAT]

Sorry, Mark Zuckerberg. Your plan to put an end to disease is a sickeningly bad idea [The Telegraph]

The Chan-Zuckerberg Initiative [In the Pipeline]

6.7.1 Bioinformatique

Microsoft vows to “solve cancer” in a decade. Hubris ensues. [Respectful Insolence]

6.9 Controverses

The NIH has shifted from being an investor in research to a consumer of research [Drug Monkey]